Aaron Seth Kesselheim

Aaron Seth Kesselheim, MD, JD, MPH

Professor of Medicine
Member, HMS Center for Bioethics

Aaron S. Kesselheim, MD, JD, MPH, is a Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Within the Division, Aaron created and leads the Program On Regulation, Therapeutics, And Law (PORTAL, www.PORTALresearch.org), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. PORTAL is now among the largest, independent academic centers focusing on these issues in the country (Twitter: @PORTAL_research, @akesselheim). Dr. Kesselheim received his medical and legal training at the University of Pennsylvania and his M.P.H. at the Harvard School of Public Health. Author of over 450 publications in the peer-reviewed medical and health policy literatures, Aaron has testified before Congress on pharmaceutical policy, medical device regulation, generic drugs, and modernizing clinical trials, is a member of the FDA Peripheral and Central Nervous System Advisory Committee, and served on a National Academies of Science, Engineering and Medicine consensus committees on addressing the opioid epidemic and bioidentical hormone replacement. At the HMS Center for Bioethics, he co-teaches a course on health policy, law, and bioethics and organizes the monthly policy and ethics consortium.

Publications View
Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures.
Authors: Authors: Brown BL, Kesselheim AS, Sarpatwari A.
PLoS Med
View full abstract on Pubmed
Estimated Medicaid Spending on Original and Citrate-Free Adalimumab From 2014 Through 2021.
Authors: Authors: Wang J, Lee CC, Kesselheim AS, Rome BN.
JAMA Intern Med
View full abstract on Pubmed
US public investment in development of mRNA covid-19 vaccines: retrospective cohort study.
Authors: Authors: Lalani HS, Nagar S, Sarpatwari A, Barenie RE, Avorn J, Rome BN, Kesselheim AS.
View full abstract on Pubmed
Patent Challenges And Litigation On Inhalers For Asthma And COPD.
Authors: Authors: Reddy S, Beall RF, Tu SS, Kesselheim AS, Feldman WB.
Health Aff (Millwood)
View full abstract on Pubmed
Insulin products and patents in the USA in 2004, 2014, and 2020: a cross-sectional study.
Authors: Authors: Van de Wiele VL, Kesselheim AS, Beran D, Darrow JJ.
Lancet Diabetes Endocrinol
View full abstract on Pubmed
Sources of Innovation in Gene Therapies - Approaches to Achieving Affordable Prices.
Authors: Authors: Vokinger KN, Avorn J, Kesselheim AS.
N Engl J Med
View full abstract on Pubmed
Estimated Medicare Part B Savings From Inflationary Rebates.
Authors: Authors: Egilman AC, Kesselheim AS, Rome BN.
View full abstract on Pubmed
Manufacturer Revenue on Inhalers After Expiration of Primary Patents, 2000-2021.
Authors: Authors: Feldman WB, Tu SS, Alhiary R, Kesselheim AS, Wouters OJ.
View full abstract on Pubmed
Therapeutic Value of Drugs Frequently Marketed Using Direct-to-Consumer Television Advertising, 2015 to 2021.
Authors: Authors: Patel NG, Hwang TJ, Woloshin S, Kesselheim AS.
JAMA Netw Open
View full abstract on Pubmed
Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021.
Authors: Authors: Roberts TJ, Kesselheim AS, Avorn J.
JAMA Netw Open
View full abstract on Pubmed

Brigham and Women's Hospital
Boston, MA 02120